AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Oncotarget
Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations
Jun 6, 2024
Dr. Blagosklonny, an expert in NSCLC treatment, discusses overcoming resistance in lung cancer therapy. He delves into the challenges with current EGFR inhibitors, the potential of Osimertinib as a third-generation TKI, and the use of preemptive combinations to enhance treatment outcomes.
08:07
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Osimertinib can be used preemptively to target resistant cells in NSCLC, extending progression-free survival.
- Preemptive combinations of Osimertinib, Afatinib, and Catmatinib aim to address multiple resistance mechanisms in NSCLC.
Deep dives
The Rise of Osemertinib as a Third-Generation EGFR TKI
Osemertinib was approved as a second-line therapy for NSCLC patients with the T790M mutation due to its ability to target this resistance mutation. This approval marked a shift in treatment strategy, as Osemertinib could be administered preemptively as a first-line treatment to prevent resistant cells from proliferating. Clinical trials showed Osemertinib significantly extended progression-free survival and response duration compared to first-generation inhibitors, highlighting its efficacy as a potent treatment option.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode